# Pharmacokinetics and Safety of HCP1303 and Co-administration of HGP1201, HIP1402 in Healthy Male Volunteers

> **NCT02712411** · PHASE1 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 30 (actual)

## Conditions studied

- Erectile Dysfunction
- Prostatic Hyperplasia

## Interventions

- **DRUG:** HCP1303
- **DRUG:** HGP1201
- **DRUG:** HIP1402

## Key facts

- **NCT ID:** NCT02712411
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2015-08
- **Final completion:** 2015-09
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2016-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02712411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02712411, "Pharmacokinetics and Safety of HCP1303 and Co-administration of HGP1201, HIP1402 in Healthy Male Volunteers". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02712411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*